BRTX

BioRestorative Therapies, Inc. Common Stock (NV)

1.14

USD

BRTX Earnings Reports

Positive Surprise Ratio

BRTX beat 12 of 15 last estimates.

80%

Next Report

Date of Next Report

Mar 25, 2026

Estimate for Q4 25 (Revenue/ EPS)

$306.00K

-$0.38

Implied change from Q3 25 (Revenue/ EPS)

+2450.00%

+15.15%

Implied change from Q4 24 (Revenue/ EPS)

+606.70%

+90.00%

BioRestorative Therapies, Inc. Common Stock (NV) earnings per share and revenue

On Nov 12, 2025, BRTX reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.36 USD, resulting in a 10.13% surprise. Revenue reached 12.00 thousand, compared to an expected 469.20 thousand, with a -97.44% difference. The market reacted with a -9.42% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 306.00 thousand USD, implying an increase of 15.15% EPS, and increase of 2450.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Lexaria Bioscience Corp. Common Stock

Report Date

Jan 13, 2026 For Q1 26

Estimate

-$0.13

Actual

-$0.07

Surprise

+47.21%

Anixa Biosciences, Inc.

Report Date

Jan 12, 2026 For Q4 25

Estimate

-$0.08

Actual

-$0.09

Surprise

-0.78%

FAQ

What were BioRestorative Therapies, Inc. Common Stock (NV)'s earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, BioRestorative Therapies, Inc. Common Stock (NV) reported EPS of -$0.33, beating estimates by 10.13%, and revenue of $12.00K, -97.44% below expectations.

How did the market react to BioRestorative Therapies, Inc. Common Stock (NV)'s Q3 2025 earnings?

The stock price moved down -9.42%, changed from $1.38 before the earnings release to $1.25 the day after.

When is BioRestorative Therapies, Inc. Common Stock (NV) expected to report next?

The next earning report is scheduled for Mar 25, 2026.

What are the forecasts for BioRestorative Therapies, Inc. Common Stock (NV)'s next earnings report?

Based on 4 analysts, BioRestorative Therapies, Inc. Common Stock (NV) is expected to report EPS of -$0.38 and revenue of $306.00K for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.